Positive Online Weight Reduction Study (POWeR2)

Conditions

Topic: Primary Care Research Network for England

Smith E, Bradbury K, Scott L, Steele M, Little P, Yardley L.

2017-05-2514 citations

Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction).

Little P, Stuart B, Hobbs FR, Kelly J, Smith ER, Bradbury KJ, Hughes S, Smith PW, Moore MV, Lean ME, Margetts BM, Byrne CD, Griffin S, Davoudianfar M, Hooper J, Yao G, Zhu S, Raftery J, Yardley L.

2017-01-0133 citations

10.3310/hta21040

An internet-based intervention with brief nurse support to manage obesity in primary care (POWeR+): a pragmatic, parallel-group, randomised controlled trial.

Little P, Stuart B, Hobbs FR, Kelly J, Smith ER, Bradbury KJ, Hughes S, Smith PW, Moore MV, Lean ME, Margetts BM, Byrne CD, Griffin S, Davoudianfar M, Hooper J, Yao G, Zhu S, Raftery J, Yardley L.

2016-07-2683 citations

10.1016/s2213-8587(16)30099-7

Does Brief Telephone Support Improve Engagement With a Web-Based Weight Management Intervention? Randomized Controlled Trial

Stephanie Hughes, Leanne Morrison, Scott Lloyd, Dawn Phillips, Beth Stuart et al. (12 authors)

Journal of Medical Internet Research2014-03-28103 citations

10.2196/jmir.3199

Interventions

1. Control, very brief advice and follow up 2. Web and minimal nurse support, minimal face to face contact with nurse

3. Web and nurse support, Web intervention with intensive nurse support Follow-up length: 12 month(s)

study entry: single randomisation only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult male and female patients with a body mass index (BMI) over 30 (or 28 with hypertension or or hypercholesterolaemia)

Exclusion criteria

Exclusion criteria: 1. Current mental health problems 2. Very ill or unable to change diet 3. Pregnancy or breastfeeding 4. Perceived inability to walk 100 metres

Design outcomes

Primary

Measure	Time frame
Outcome measure (08/12/2015): 1. The average weight reduction over 12 months, measured blind to randomisation group using Tanita digital scales measured at baseline, 6, and 12 months. 2. A secondary analysis of weight is the number of individuals who maintain a clinically important 5% weight reduction measured using Tanita digital scales measured at 6 and 12 months. Original outcome measure: Weight measured at baseline, 6, and 12 months	—

Measure

Time frame

Outcome measure (08/12/2015): 1. The average weight reduction over 12 months, measured blind to randomisation group using Tanita digital scales measured at baseline, 6, and 12 months. 2. A secondary analysis of weight is the number of individuals who maintain a clinically important 5% weight reduction measured using Tanita digital scales measured at 6 and 12 months. Original outcome measure: Weight measured at baseline, 6, and 12 months

—

Secondary

Measure	Time frame
1. Food and drink consumption measured using Food Frequency Questionnaires at baseline, 6, and 12 months 2. Physical activity measured using the Godin physical activity questionnaire at baseline, 6, and 12 months 3. Waist circumference in cm measured by tape measure at baseline, 6, and 12 months 4. Blood pressure (BP) in mm Hg measured using a validated Omron device at baseline, 6, and 12 months 5. Serum Glucose and HbA1c in mmol/l measured at baseline, 6, and 12 months 6. Serum lipids (cholesterol/HDL/LDL/triglyceride) in mmol/l measured at baseline, 6, and 12 months 7. Body composition measured using Tanita digital scales to document percentage body fat measured at baseline, 6, and 12 months 8. Serum Liver function tests (AST,ALT,GGT) measured in IU/l to monitor non-alcoholic fatty liver disease at baseline, 6, and 12 months 9. Serum Ferritin in ug/l measured at 12 months 10.A modified version of the Patient Enablement Instrument measured by self-report questionnaire at baseline and 12 months 11. EQ-5D for Health economic analyses measured by self-report questionnaire at baseline, 6, and 12 months. 12. Health service resource use measured from documentation in the medical records in the 12 months prior to randomisation and the 12 months following 13. Reported activities undertaken to lose weight measured by self-report questionnaire at 12 months	—

Measure

Time frame

1. Food and drink consumption measured using Food Frequency Questionnaires at baseline, 6, and 12 months 2. Physical activity measured using the Godin physical activity questionnaire at baseline, 6, and 12 months 3. Waist circumference in cm measured by tape measure at baseline, 6, and 12 months 4. Blood pressure (BP) in mm Hg measured using a validated Omron device at baseline, 6, and 12 months 5. Serum Glucose and HbA1c in mmol/l measured at baseline, 6, and 12 months 6. Serum lipids (cholesterol/HDL/LDL/triglyceride) in mmol/l measured at baseline, 6, and 12 months 7. Body composition measured using Tanita digital scales to document percentage body fat measured at baseline, 6, and 12 months 8. Serum Liver function tests (AST,ALT,GGT) measured in IU/l to monitor non-alcoholic fatty liver disease at baseline, 6, and 12 months 9. Serum Ferritin in ug/l measured at 12 months 10.A modified version of the Patient Enablement Instrument measured by self-report questionnaire at baseline and 12 months 11. EQ-5D for Health economic analyses measured by self-report questionnaire at baseline, 6, and 12 months. 12. Health service resource use measured from documentation in the medical records in the 12 months prior to randomisation and the 12 months following 13. Reported activities undertaken to lose weight measured by self-report questionnaire at 12 months

—

Countries

United Kingdom

Outcome results

None listed